New mouse models to understand hepatitis B virus infection
Official title: Novel mouse models of hepatitis B virus infection and replication
Funded at Wake Forest University Health Sciences · NIH-11123189 · Data updated 2026-11-12
This study is creating special mouse models to help scientists learn more about how hepatitis B virus (HBV) stays in the body and to find new treatments that could help the millions of people living with this virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | June 21, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $711,641 |
| NIH project number | 5R01AI183855-02 |
| Project ID | NIH-11123189 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are chronically infected with hepatitis B virus and are seeking new treatment options.
✕Less likely to help
Patients who are not infected with hepatitis B virus or those who have already achieved a complete cure may not benefit from this research.
What this research studies
This research focuses on developing novel mouse models to study hepatitis B virus (HBV) infection and replication. By creating these models, researchers aim to better understand how HBV persists in the body and to identify new antiviral therapies that could effectively eliminate the virus. The study will utilize advanced cell culture techniques and explore the role of specific receptors involved in HBV infection. This approach is crucial for discovering new treatments for the millions of people already infected with HBV.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral therapies that eliminate hepatitis B virus infection.
How similar studies have gone: Other research has shown promise in developing antiviral therapies for hepatitis B, but this approach using novel mouse models is relatively new and untested.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Luo, Guangxiang George — Wake Forest University Health Sciences
- Study coordinator: Luo, Guangxiang George
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
HBV safety with long-acting HIV therapy for people with HIV
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.